We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA
Read MoreHide Full Article
AstraZeneca plc (AZN - Free Report) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation. The drug has also been granted a priority review status with a PDUFA date set for the third quarter of 2017.
The acceptance of the NDA was based on positive results from a phase III study, SOLO-2. The priority review status from the FDA will speed up the review of the NDA within 6 months of submission compared with the standard 10-month review timeline. AstraZeneca’s shares have outperformed the Zacks classified Large Cap Pharma industry so far this year. Its shares have increased 14.7%, while the industry gained 6.8%.
The SOLO-2 study evaluating germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients, met its primary end point. Data from the study showed that Lynparza tablets reduced risk of disease progression by 70% and met investigator-assessed progression-free survival (PFS) of 19.1 months vs 5.5 months compared to placebo.
Results were presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Going forward, if the tablet formulation receives approval, the 300mg twice-daily tablet dose will reduce the pill burden for patient.
We note that Lynparza capsules (400mg twice daily) are currently approved in the U.S. as a monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy.
The drug has registered sales of $218 million in 2016 compared with $94 million in 2015.
However, Lynparza tablets are still in investigational formulation and are not FDA-approved for any indication.
Meanwhile, AstraZeneca is also evaluating the potential of Lynparza in other PARP dependent tumors. Currently, phase III studies on Lynparza are ongoing for several indications like breast cancer, pancreatic cancer and prostate cancer among others along with additional studies being planned.
Clovis Oncology, Inc.’s advanced ovarian cancer treatment, Rubraca tablets, was approved by the FDA in December last year. Clovis in-licensed Rubraca from Pfizer, Inc. (PFE - Free Report) in 2011.
Roche’s earnings estimates increased from $1.70 to $1.90 for 2017 over the last 30 days.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA
AstraZeneca plc (AZN - Free Report) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation. The drug has also been granted a priority review status with a PDUFA date set for the third quarter of 2017.
The acceptance of the NDA was based on positive results from a phase III study, SOLO-2. The priority review status from the FDA will speed up the review of the NDA within 6 months of submission compared with the standard 10-month review timeline. AstraZeneca’s shares have outperformed the Zacks classified Large Cap Pharma industry so far this year. Its shares have increased 14.7%, while the industry gained 6.8%.
The SOLO-2 study evaluating germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients, met its primary end point. Data from the study showed that Lynparza tablets reduced risk of disease progression by 70% and met investigator-assessed progression-free survival (PFS) of 19.1 months vs 5.5 months compared to placebo.
Results were presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Going forward, if the tablet formulation receives approval, the 300mg twice-daily tablet dose will reduce the pill burden for patient.
We note that Lynparza capsules (400mg twice daily) are currently approved in the U.S. as a monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy.
The drug has registered sales of $218 million in 2016 compared with $94 million in 2015.
However, Lynparza tablets are still in investigational formulation and are not FDA-approved for any indication.
Meanwhile, AstraZeneca is also evaluating the potential of Lynparza in other PARP dependent tumors. Currently, phase III studies on Lynparza are ongoing for several indications like breast cancer, pancreatic cancer and prostate cancer among others along with additional studies being planned.
Clovis Oncology, Inc.’s advanced ovarian cancer treatment, Rubraca tablets, was approved by the FDA in December last year. Clovis in-licensed Rubraca from Pfizer, Inc. (PFE - Free Report) in 2011.
Zacks Rank & Key Picks
AstraZeneca is a Zacks Rank #3 (Hold) stock. A better-ranked stock in the Large Cap Pharma sector is Roche Holding AG (RHHBY - Free Report) , which holds a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Roche’s earnings estimates increased from $1.70 to $1.90 for 2017 over the last 30 days.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>